Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 12:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 1,564 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control regimen Clear all
Active, not recruiting Phase 3 Interventional

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

NCT05196035
View directory record Official record
Conditions
Chronic Kidney Disease, Proteinuria
Interventions
Finerenone (Kerendia, BAY94-8862), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
6 Months to 17 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Palo Alto, California • San Diego, California • Hollywood, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 28, 2026, 12:45 PM EDT
Not yet recruiting Not applicable Interventional

Home-Based Lower-Extremity Heat Therapy for Walking Function in Peripheral Artery Disease

NCT07653243
View directory record Official record
Conditions
PAD, PAD - Peripheral Arterial Disease
Interventions
Lower-Extremity Heat Therapy, Sham Lower-Extremity Heat Therapy
Device
Lead sponsor
Aquilo Sports, LLC
Industry
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 28, 2026, 12:45 PM EDT
Recruiting Phase 2 Interventional

A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)

NCT05488340
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
LBP-EC01 0.1 x IV dose, LBP-EC01 0.01x IV Dose, LBP-EC01 IV Infusion Dose, Placebo, LBP-EC01, TMP/SMX
Drug
Lead sponsor
Locus Biosciences
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
17
States / cities
Fresno, California • Lancaster, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 28, 2026, 12:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin

NCT00147225
View directory record Official record
Conditions
Solid Tumors, Advanced Cancer
Interventions
AMG 531, Carboplatin, Adriamycin, Ifosfamide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Oct 28, 2026, 12:45 PM EDT
Completed Phase 2Phase 3 Interventional

Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)

NCT04372589
View directory record Official record
Conditions
COVID-19, Pneumonia
Interventions
Heparin
Drug
Lead sponsor
University of Manitoba
Other
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
13
States / cities
Atlanta, Georgia • Chicago, Illinois • Jefferson, Louisiana + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Oct 28, 2026, 12:45 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Osteopathic Manipulative Treatment and Migraine Headaches

NCT04976985
View directory record Official record
Conditions
Chronic Migraine, Migraine Disorders, Headache Disorders, Headache, Migraine
Interventions
Osteopathic Manipulative Therapy (OMT), Standard of care
Procedure · Other
Lead sponsor
St. Luke's Hospital, Pennsylvania
Other
Eligibility
18 Years to 50 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 28, 2026, 12:45 PM EDT
Completed Not applicable Interventional

Effectiveness of Public Health Model of Latent Tuberculosis Infection Control for High-Risk Adolescents

NCT00233168
View directory record Official record
Conditions
Lung Diseases, Tuberculosis
Interventions
Adherence Program, Life Skills and Self-Esteem Training Program (Attention Control Arm)
Behavioral
Lead sponsor
San Diego State University
Other
Eligibility
13 Years to 18 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Oct 28, 2026, 12:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Feasibility and Efficacy of A Remote Tai Chi Program in Older Adults

NCT06918678
View directory record Official record
Conditions
Aging
Interventions
Tai Chi intervention, Usual care condiition
Device · Other
Lead sponsor
The University of Tennessee, Knoxville
Other
Eligibility
60 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 28, 2026, 12:45 PM EDT
Active, not recruiting Phase 2 Interventional

Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)

NCT07486960
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Tulisokibart, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
18
States / cities
Sun City, Arizona • Tucson, Arizona • Riverside, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 28, 2026, 12:45 PM EDT
Recruiting Not applicable Interventional

Cryocompression for CIPN

NCT07064798
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy, Taxane-Induced Peripheral Neuropathy, CIPN - Chemotherapy-Induced Peripheral Neuropathy
Interventions
Paxman Limb Cryocompression System
Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 28, 2026, 12:45 PM EDT
Not listed Not applicable Interventional

Oscillation and Lung Expansion Therapy in Patients With COVID-19

NCT04582214
View directory record Official record
Conditions
COVID-19, Oscillation and Lung Expansion
Interventions
MetaNeb® System
Device
Lead sponsor
Hill-Rom
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Atlanta, Georgia • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 28, 2026, 12:45 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140

NCT02483078
View directory record Official record
Conditions
HIV
Interventions
PRO 140, Placebo, Optimized Background Regimen
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
34
States / cities
Fountain Valley, California • Long Beach, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Oct 28, 2026, 12:45 PM EDT
Completed Phase 2 Interventional

Evaluation of Soluble Epoxide Hydrolase (s-EH) Inhibitor in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance

NCT00847899
View directory record Official record
Conditions
Hypertension, Impaired Glucose Tolerance
Interventions
AR9281, Placebo
Drug
Lead sponsor
Arete Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
30
States / cities
Mobile, Alabama • Muscle Shoals, Alabama • Anaheim, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2009 · Synced Oct 28, 2026, 12:45 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Botanical Skin Care Regimen on Mild to Moderate Acne and the Microbiome

NCT05271487
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Multi-Step Botanical Skin Care Regimen
Other
Lead sponsor
Integrative Skin Science and Research
Industry
Eligibility
15 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 28, 2026, 12:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Pharmacokinetics, Safety, and Tolerability of Intravenous ETX2514 and Sulbactam Administered Concurrently to Subjects With Various Degrees of Renal Impairment and Healthy Matched Control Subjects

NCT03310463
View directory record Official record
Conditions
Acinetobacter Baumannii Infection
Interventions
ETX2514SUL
Drug
Lead sponsor
Entasis Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Lakewood, Colorado • Miami, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 28, 2026, 12:45 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of Efficacy, Cycle Control, and Safety of a NES-E2 Contraceptive Vaginal Ring

NCT03432416
View directory record Official record
Conditions
Healthy Women, Female Contraception
Interventions
NES-E2 CVR
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
385 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
11
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 28, 2026, 12:45 PM EDT
Recruiting Not applicable Interventional

Clinical Trial of Blenderized Tube Feeds Varying in Viscosity

NCT05417958
View directory record Official record
Conditions
Feeding Disorders
Interventions
Extremely thick blenderized tube feed, Mildly thick blenderized tube feed
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Year and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 28, 2026, 12:45 PM EDT
Completed Not applicable Interventional

Intensive Discharge Intervention in Diabetes

NCT02122926
View directory record Official record
Conditions
Type II Diabetes, Cardiovascular Disease
Interventions
Intensive discharge intervention
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 25, 2014 · Synced Oct 28, 2026, 12:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Meditation and Opioid Consumption in Total Joint Replacement Patients Undergo Primary Total Hip and Knee Replacement

NCT05669066
View directory record Official record
Conditions
Arthropathy of Knee, Osteo Arthritis Knee, Osteonecrosis, Meditation, Knee Osteoarthritis, Knee Disease, Knee Injuries, Opioid Use, Opioid Dependence, Opioid Use Disorder
Interventions
Mindful meditation
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 89 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 30, 2022 · Synced Oct 28, 2026, 12:45 PM EDT
Completed Phase 3 Interventional

Evaluation of Galantamine in the Treatment of Alzheimer's Disease

NCT00000172
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Galantamine
Drug
Lead sponsor
Janssen, LP
Industry
Eligibility
0 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
55
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Berkeley, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 28, 2026, 12:45 PM EDT
Completed Phase 3 Interventional Results available

ACTH for Fatigue in Multiple Sclerosis Patients

NCT02315872
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
ACTH, Placebo
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Cullman, Alabama • Medford, Oregon • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Oct 28, 2026, 12:45 PM EDT
Not yet recruiting Not applicable Interventional

Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer

NCT07325214
View directory record Official record
Conditions
Pancreatic Cancer, Borderline Resectable Pancreatic Cancer, Locally Advanced Pancreatic Cancer
Interventions
IMD10, chemotherapy regimen [irinotecan hydrochloride, oxaliplatin, fluorouracil (5-FU) and leucovorin]
Device · Drug
Lead sponsor
IMGT Co., Ltd.
Industry
Eligibility
18 Years to 85 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Boston, Massachusetts • San Antonio, Texas • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 28, 2026, 12:45 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

NCT01197755
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
fostamatinib, placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
67
States / cities
Anniston, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 64 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2014 · Synced Oct 28, 2026, 12:45 PM EDT
Terminated Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease

NCT04766476
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
BMS-963272, Placebo matching BMS-963272
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
19
States / cities
Cullman, Alabama • Chandler, Arizona • Tucson, Arizona + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Oct 28, 2026, 12:45 PM EDT